AMCP Market Insights Health Plan Best Practices: Targeted Therapies to Deliver Improved Patient Outcomes in Oncology

This non-promotional, sponsored webinar will review health plan best practice recommendations for targeted therapies in oncology with an impressive panel of oncology and managed care experts.

As the US Market continues to evolve, so does the complexity of payers and providers navigating best practices that ensure their members have access to high-quality, cost-effective medications. AMCP’s Market Insights Best Practice provides recommendations from our managed care members to help their peers make the best coverage and access decisions.

Oncology is seeing accelerated development of new expression-based therapy classes with the potential to deliver unprecedented improvements in patient outcomes. One class of particular interest is antibody-drug conjugates (ADCs). ADCs are amongst the fastest growing drug classes in oncology, as they combine the best features of monoclonal antibodies and small molecule drugs, creating a single moiety that is highly specific and cytotoxic. Managed care and payer professionals play a central role in improving value in and access to cancer care.

In this webinar, a panel of experts discusses health plan best practices related to target therapies in oncology. Following the presentation, join the panelists for a live Q&A session.

Learn About:

At the completion of this activity, participants should be able to:

• Discuss key insights into the benefits of antibody drug conjugates and site of care administration
• Describe practices for the evidence evaluation of antibody drug conjugates and strategies to improve transparency of coverage policies
• Explore health plan practices which support the safe use of antibody drug conjugates
• Examine strategies available to managed care professionals to guide treatment sequencing of antibody drug conjugates
• Identify components of high-quality care that improve health equity and address unmet needs in cancer care

Expert Faculty:

 

Jim Kenney, RPh, MBA (Moderator)
Founder and President
JTKenney, LLC

    
Laura Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth

    
Christopher Fausel, PharmD, MHA, BCOP
Clinical Manager
Oncology Pharmacy, Indiana University Health

    
Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Assistant Vice President – System Oncology Pharmacy
Baptist Health South Florida

    
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC
Director of Pharmacy
Minnesota Oncology

    
Ryan Haumschild, PharmD, MS, MBA
Director of Pharmacy Services
Emory Healthcare and Winship Cancer Institute

    
Dana McCormick, RPh, FAMCP
Director of Pharmacy
Blue Cross Blue Shield of Texas

    
Tim Mok, PharmD, BCPS, BCOP
Hematology Oncology Pharmacy Research Analyst
Kaiser Permanente

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, registered nurses, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.